Skip to main content
Pre-ACR25 (10.24.2025)
Dr. Jack Cush reviews the news and info reports the day before ACR 2025
Clinical and Genetic Effects of Neuropsychiatric Lupus

The clinical features and genetic abnormalities of neuropsychia

Dr. John Cush RheumNow

11 months 1 week ago
Clinical and Genetic Effects of Neuropsychiatric Lupus The clinical features and genetic abnormalities of neuropsychiatric systemic lupus erythematosus shows that NPSLE often means more severe lupus and more organ involvement beyond the central nervous system. https://t.co/7Ujo6Kaf1N
REPLENISH - Secukinumab Works in Polymyalgia Rheumatica

Novartis announced the results of their REPLENISH trial showin

Dr. John Cush RheumNow

11 months 1 week ago
REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR). https://t.co/qa9RzmNFU4 https://t.co/dCEkelJzni
Colchicine Ineffective in Long COVID

Management of long COVID has been perplexing with symptoms having functional and

Dr. John Cush RheumNow

11 months 1 week ago
Colchicine Ineffective in Long COVID Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory https://t.co/9E3dvUFqJP
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease

SGLT-2 inhibitors offer benefits beyond glycemic

Dr. John Cush RheumNow

11 months 1 week ago
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and https://t.co/O4Pi8GyT32
Stress Raises the Risk of Psoriasis
  • EurekAlert!
New longitudinal research reveals that severe stress caused by changes in family structure like divorce or separation experienced during the first year of life may triple the risk of developing psoriasis later in life.
Can Steroids Be Stopped in Lupus Nephritis?
  • MedPage Today
Patients with lupus nephritis were more likely to get off chronic corticosteroid treatment, and stay off, when certain factors were in place, researchers said.
Single center study ANCA-assoc. vasculitis. From 78 pts had poor outcomes (16 ESKD, 15 deaths). Elevated BUN was a risk

Dr. John Cush RheumNow

11 months 1 week ago
Single center study ANCA-assoc. vasculitis. From 78 pts had poor outcomes (16 ESKD, 15 deaths). Elevated BUN was a risk factor (adj HR 1.07). Risk factors for ESKD were baseline BUN & WBC. Risks for death included CV Dz (HR 8.7), NLR (1.04) &anti-PLt Rx (HR 6.8) https://t.co/QQrDmja0zo
5–10% of axSpA [ts jave comorbid IBD. Southern Swedish study 152 (r- & nr-) axSpA pts found elevated fecal calprot

Dr. John Cush RheumNow

11 months 1 week ago
5–10% of axSpA [ts jave comorbid IBD. Southern Swedish study 152 (r- & nr-) axSpA pts found elevated fecal calprotectin (≥ 50 mg/kg) & this was assoc. w/ more damage w/ higher mSASSS values for all axSpA (adj OR 2.2) & in r-axSpA (adj OR 2.9) https://t.co/Hi1lE4so1r https://t.co/YYCGYYasfL
6-week intensive smoking cessation prg studied in 94 RA daily smokers in remission or low Dz activity (DAS28-CRP=2.9). A

Dr. John Cush RheumNow

11 months 1 week ago
6-week intensive smoking cessation prg studied in 94 RA daily smokers in remission or low Dz activity (DAS28-CRP=2.9). At 3 mos the intervention group had higher cessation rates; but had no effect on EULAR responses, TJC, or CRP (result actually favoured the controls) https://t.co/HPJYeyPCPQ
From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect:
• KOL videos
• Clinical tr

Dr. John Cush RheumNow

11 months 1 week ago
From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect: • KOL videos • Clinical trial highlights • Daily faculty recaps • Live streaming #ACR25 #Rheumatology #ClinicalTrials https://t.co/IdH5HIQAQX
FDA Approves Obinutuzumab for Active Lupus Nephritis

The FDA has approved obinutuzumab (Gazyva) for the treatment of l

Dr. John Cush RheumNow

11 months 1 week ago
FDA Approves Obinutuzumab for Active Lupus Nephritis The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis. https://t.co/WbpATY86BY https://t.co/zRONkCUtIx
The clinical features and genetic abnormalities of neuropsychiatric systemic lupus erythematosus shows that NPSLE often means more severe lupus and more organ involvement beyond the central nervous system.
Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab in adults with polymyalgia rheumatica (PMR).
×